Publicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (16)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

  3. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  4. Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients’ healthcare in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1319-1328

  5. Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy

    Clinical and Translational Oncology

  6. SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2771-2782

  7. Spanish Society of Medical Oncology recommendations for comprehensive assessment and care of cancer survivors’ needs

    Clinical and Translational Oncology

  8. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2016

  1. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1237-1242

2011

  1. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

    Investigational New Drugs, Vol. 29, Núm. 5, pp. 1038-1044

2010

  1. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (SOGUG-02-06)

    The Lancet Oncology, Vol. 11, Núm. 4, pp. 350-357

  2. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection

    Journal of Virology, Vol. 84, Núm. 1, pp. 475-481

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

1985

  1. Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma: Preliminary results

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 8, Núm. 3, pp. 200-209